Annovis Bio Appoints New CMO, Elects Director
Ticker: ANVS · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | Sep 29, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $450,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, board-election, compensation
TL;DR
Annovis Bio swaps CMOs and adds a director. New CMO gets $450k + options.
AI Summary
Annovis Bio, Inc. announced on September 25, 2025, the departure of Dr. Michael J. McVicar as Chief Medical Officer. The company also elected Dr. Maria L. Maccecchini as a Class II Director and appointed Dr. Joseph E. Please as Chief Medical Officer, effective September 25, 2025. Dr. Please will receive an annual salary of $450,000 and stock options.
Why It Matters
The appointment of a new Chief Medical Officer and the election of a new director can signal strategic shifts or new leadership directions for the company's drug development pipeline.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially the Chief Medical Officer, can indicate internal challenges or strategic realignments that may impact the company's future performance.
Key Numbers
- $450,000 — Annual Salary (for the new Chief Medical Officer, Dr. Joseph E. Please.)
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- Dr. Michael J. McVicar (person) — Departing Chief Medical Officer
- Dr. Maria L. Maccecchini (person) — Elected Class II Director
- Dr. Joseph E. Please (person) — Appointed Chief Medical Officer
- $450,000 (dollar_amount) — Annual salary for new CMO
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Joseph E. Please was appointed as the new Chief Medical Officer, effective September 25, 2025.
What is the annual salary for the new Chief Medical Officer?
The annual salary for Dr. Joseph E. Please is $450,000.
Who has departed from their role as Chief Medical Officer?
Dr. Michael J. McVicar has departed from his role as Chief Medical Officer.
Who has been elected as a Class II Director?
Dr. Maria L. Maccecchini has been elected as a Class II Director.
What is the effective date of the leadership changes?
The leadership changes, including the appointment of the new CMO and election of the director, are effective September 25, 2025.
Filing Stats: 590 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-09-29 16:31:24
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang
- $450,000 — ll receive (i) an annual base salary of $450,000, (ii) an annual target bonus of 40%, (i
Filing Documents
- tm2527170d1_8k.htm (8-K) — 26KB
- tm2527170d1_ex99-1.htm (EX-99.1) — 11KB
- 0001104659-25-094522.txt ( ) — 204KB
- anvs-20250925.xsd (EX-101.SCH) — 3KB
- anvs-20250925_lab.xml (EX-101.LAB) — 33KB
- anvs-20250925_pre.xml (EX-101.PRE) — 22KB
- tm2527170d1_8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits Exhibit Number Description 99.1 Press Release dated September 25, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: September 29, 2025 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer